NASDAQ:TNDM Tandem Diabetes Care (TNDM) Stock Forecast, Price & News $21.07 +0.30 (+1.44%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$20.60▼$21.0750-Day Range$19.33▼$36.2252-Week Range$19.11▼$58.82Volume74,631 shsAverage Volume1.29 million shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$46.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Tandem Diabetes Care MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside125.3% Upside$46.80 Price TargetShort InterestBearish12.66% of Shares Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment1.34Based on 7 Articles This WeekInsider TradingAcquiring Shares$21,450 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.49) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector153rd out of 968 stocksSurgical & Medical Instruments Industry24th out of 101 stocks 4.2 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.80, Tandem Diabetes Care has a forecasted upside of 125.3% from its current price of $20.77.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.66% of the outstanding shares of Tandem Diabetes Care have been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Tandem Diabetes Care has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Tandem Diabetes Care is -0.64. Previous Next 4.1 News and Social Media Coverage News SentimentTandem Diabetes Care has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tandem Diabetes Care this week, compared to 4 articles on an average week.Search Interest14 people have searched for TNDM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,450.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Tandem Diabetes Care is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.49) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tandem Diabetes Care (NASDAQ:TNDM) StockTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Read More TNDM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNDM Stock News HeadlinesSeptember 29, 2023 | barrons.comDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the FirmSeptember 29, 2023 | finance.yahoo.com2 Stocks Under $25 to Buy and Hold for 10 YearsOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 27, 2023 | benzinga.comTNDM Investors Have Opportunity to Lead Tandem Diabetes Care, Inc. Securities Fraud LawsuitSeptember 26, 2023 | gurufocus.comDecoding Tandem Diabetes Care Inc (TNDM)'s Performance Potential: A Deep Dive into Key MetricsSeptember 26, 2023 | finance.yahoo.comInvesting in Tandem Diabetes Care (TNDM): Navigating the Thin Line Between Value and TrapSeptember 24, 2023 | stockhouse.comTNDM INVESTOR NOTICE: Tandem Diabetes Care, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 24, 2023 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Reaches New 12-Month Low at $20.64October 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 22, 2023 | benzinga.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tandem Diabetes Care, Inc. (TNDM)September 21, 2023 | benzinga.comTNDM Shareholder Alert: Investors with Large Losses Should Contact Robbins LLP for Information About Recovery Against Tandem Diabetes Care, Inc.September 19, 2023 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) InvestorsSeptember 18, 2023 | technews.tmcnet.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) InvestorsSeptember 15, 2023 | tmcnet.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of InvestorsSeptember 15, 2023 | benzinga.comTandem Diabetes Care, Inc. (TNDM) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Tandem Diabetes Care, Inc.September 15, 2023 | finance.yahoo.comUnraveling the Future of Tandem Diabetes Care Inc (TNDM): A Deep Dive into Key MetricsSeptember 15, 2023 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of InvestorsSeptember 14, 2023 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of InvestorsSeptember 13, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of InvestorsSeptember 13, 2023 | stockhouse.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the FirmSeptember 13, 2023 | benzinga.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. (TNDM)September 13, 2023 | businesswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TNDMSeptember 11, 2023 | technews.tmcnet.comShareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Tandem Diabetes Care, Inc.September 8, 2023 | cnbc.comObesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buyingSeptember 7, 2023 | msn.comInsulet, Tandem Diabetes drop as weight loss drugs impact insulin useSeptember 7, 2023 | finance.yahoo.comIs Tandem Diabetes Care (TNDM) Too Good to Be True? A Comprehensive Analysis of a Potential ...September 7, 2023 | finance.yahoo.comIs Tandem Diabetes Care Inc (TNDM) Set to Underperform? Analyzing the Factors Limiting GrowthSee More Headlines Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address TNDM Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,600Year Founded2006Price Target and Rating Average Stock Price Forecast$46.80 High Stock Price Forecast$75.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+125.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,590,000.00 Net Margins-28.40% Pretax Margin-28.05% Return on Equity-20.29% Return on Assets-7.76% Debt Debt-to-Equity Ratio0.86 Current Ratio4.38 Quick Ratio3.53 Sales & Book Value Annual Sales$790.35 million Price / Sales1.71 Cash FlowN/A Price / Cash FlowN/A Book Value$6.84 per share Price / Book3.04Miscellaneous Outstanding Shares65,078,000Free Float63,451,000Market Cap$1.35 billion OptionableOptionable Beta0.87 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John F. Sheridan (Age 68)Pres, CEO & Director Comp: $1.23MMs. Leigh A. Vosseller (Age 50)Exec. VP, CFO & Treasurer Comp: $665.43kMr. David B. Berger Esq. (Age 53)Exec. VP & COO Comp: $670.18kMs. Susan M. Morrison (Age 44)Exec. VP & Chief Admin. Officer Comp: $674.76kMr. Brian B. Hansen (Age 55)Exec. VP & Chief Commercial Officer Comp: $650.19kMs. Elizabeth Anne Gasser (Age 46)Exec. VP & Chief Strategy Officer Comp: $606.83kMr. Rick A. Carpenter (Age 60)Chief Technical Officer Ms. Shannon M. Hansen (Age 57)Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. Mr. Ross SylviaVP of MarketingMr. Tom FoxSr. VP of HR & Organizational Devel.More ExecutivesKey CompetitorsPROCEPT BioRoboticsNASDAQ:PRCTLeMaitre VascularNASDAQ:LMATAlphatecNASDAQ:ATECParagon 28NYSE:FNAMiMedx GroupNASDAQ:MDXGView All CompetitorsInsiders & InstitutionsKathleen Mcgroddy-GoetzBought 1,000 shares on 9/15/2023Total: $21,450.00 ($21.45/share)Alberta Investment Management CorpBought 189,249 shares on 8/24/2023Ownership: 0.291%Virginia Retirement Systems ET ALBought 19,200 shares on 8/22/2023Ownership: 0.030%California State Teachers Retirement SystemSold 1,899 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 6,078 shares on 8/21/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions TNDM Stock - Frequently Asked Questions Should I buy or sell Tandem Diabetes Care stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares. View TNDM analyst ratings or view top-rated stocks. What is Tandem Diabetes Care's stock price forecast for 2023? 12 brokerages have issued twelve-month price objectives for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $30.00 to $75.00. On average, they expect the company's stock price to reach $46.80 in the next year. This suggests a possible upside of 125.3% from the stock's current price. View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts. How have TNDM shares performed in 2023? Tandem Diabetes Care's stock was trading at $44.95 at the beginning of the year. Since then, TNDM shares have decreased by 53.8% and is now trading at $20.77. View the best growth stocks for 2023 here. When is Tandem Diabetes Care's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our TNDM earnings forecast. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its earnings results on Thursday, August, 3rd. The medical device company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.24. The medical device company earned $195.92 million during the quarter, compared to analyst estimates of $201.62 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 20.29% and a negative net margin of 28.40%. What ETFs hold Tandem Diabetes Care's stock? ETFs with the largest weight of Tandem Diabetes Care (NASDAQ:TNDM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Harbor Corporate Culture Small Cap ETF (HAPS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Syntax Stratified SmallCap ETF (SSLY).iShares U.S. Medical Devices ETF (IHI). When did Tandem Diabetes Care's stock split? Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $785.00M-, compared to the consensus revenue estimate of $881.47 million. What is John Sheridan's approval rating as Tandem Diabetes Care's CEO? 11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL). What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." How do I buy shares of Tandem Diabetes Care? Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $20.77. How much money does Tandem Diabetes Care make? Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $1.35 billion and generates $790.35 million in revenue each year. The medical device company earns $-94,590,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. How many employees does Tandem Diabetes Care have? The company employs 2,600 workers across the globe. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com. This page (NASDAQ:TNDM) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.